Painreform is trading at $1.05 (+6.96%) as the stock rebounds from a 7.38% drop to $0.99 on July 29, 2026.
- The upward move appears to be a short-term bounce following a multi-day decline, as no fresh company-specific announcements, earnings updates, or FDA events have been reported.
- The price action is consistent with a broader risk-on market tone, with U.S. equities trading significantly higher and the Nasdaq gaining 2.47%.